Table 2 A comparison of rheumatoid arthritis and psoriatic arthritis outcomes at biologic initiation, one year and 12 year reviews

 Adalimumab

144 (52.6%)

47 (36.4%)

0.002

76 (44.7%)

27 (31.0%)

0.034

43 (25.6%)

28 (33.3%)

NS

 Etanercept

100 (36.5%)

68 (52.7%)

0.002

62 (36.5%)

45 (51.7%)

0.019

48 (28.6%)

30 (35.7%)

NS

 Infliximab

18 (6.6%)

14 (10.9%)

NS

13 (7.6%)

11 (12.6%)

NS

3 (1.8%)

8 (9.5%)

0.004

 Rituximab

12 (4.4%)

0

0.011

4 (2.4%)

0

NS

16 (9.5%)

0

0.004

 Other^a

0

0

1 (0.6%)

0

NS

24 (14.3%)

8 (9.5%)

NS

 None

0

0

14 (5.1%)

4 (3.1%)

NS

34 (20.2%)

10 (11.9%)

NS

Biologic persistence

n/a

n/a

n/a

136 (49.6%)

76 (58.9%)

NS

66 (38.2%)

45 (52.3%)

NS

Methotrexate

176 (64.2%)

35 (27.3%)

<0.001

108 (64.8%)

21 (24.4%)

<0.001

72 (42.2%)

22 (25.9%)

0.008

PGH, mm

60 (0-100)

50 (0-100)

NS

30 (0-100)

20 (0-90)

<0.001

50 (0-100)

5 (0-100)

<0.001

TJC28

9 (0-28)

6 (0-28)

<0.001

1 (0-28)

0 (0-20)

<0.001

0 (0-19)

0 (0-2)

0.019

SJC28

9 (0-28)

5 (0-28)

<0.001

1 (0-28)

0 (0-25)

<0.001

0 (0-15)

0 (0-2)

<0.001

CRP, mg/L

16 (2-158)

9 (0-108)

<0.001

4 (1-138)

4 (0-41)

0.034

3 (1-65)

2 (1-46)

<0.001

 Low

9 (3.5%)

13 (11.1%)

0.003

91 (55.2%)

60 (82.2%)

<0.001

83 (79.8%)

22 (95.7%)

NS

 Moderate

89 (34.4%)

65 (55.6%)

<0.001

58 (35.2%)

10 (13.7%)

0.001

20 (19.2%)

1 (4.3%)

0.012

 High

160 (61.8%)

39 (33.3%)

<0.001

16 (9.7%)

3 (4.1%)

NS

1 (1%)

0 (0%)

NS

36 (28.1%)

5 (8.6%)

0.003

51 (31.9%)

12 (15.0%)

0.005